iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy
A medicine company tested a new treatment that helped reduce serious health crises in sick patients by a lot. When a company shows that their medicine works better and is safe, people pay attention to whether the company might succeed.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.